Addus Q3 EPS $1.54, Adjusted EPS Up 17.3% to $1.83 on 7.0% Revenue Growth
ADUS sits 41% above its 52-week low of $87.95 on elevated volume (2.1× avg).
Summary
Addus reported Q3 2026 revenue of $387.7 million (+7.0%) and adjusted EPS of $1.83 (+17.3%), with adjusted EBITDA up 13.5% to $51.2 million. The company reiterated its pending $275 million AccentCare personal care acquisition and holds $98.5 million of cash against $24.3 million of debt.
Key Events · Earnings and Guidance · ADUS
-
Q3 Revenue Grows 7.0% to $387.7M
Net service revenues rose to $387.7 million from $362.3 million a year ago, with personal care up 6.9% organically and hospice average daily census up 4.3%.
-
Adjusted EPS Jumps 17.3% to $1.83
Net income was $28.6 million, or $1.54 per diluted share, versus $22.8 million and $1.24 a year ago; adjusted EBITDA increased 13.5% to $51.2 million.
-
Balance Sheet Funds AccentCare Deal
The company held $98.5 million of cash against $24.3 million of bank debt, with $617.8 million available under its revolver, supporting the pending $275 million AccentCare personal care acquisition.
-
AccentCare Close Awaits Regulatory Approval
The $275 million deal, expected to add roughly $280 million in annualized revenue, remains subject to regulatory approvals and customary closing conditions.
Analysis · ADUS · Industrial Applications And Services
The margin story is the point here: revenue rose 7.0% to $387.7 million and adjusted EPS climbed 17.3% to $1.83, with adjusted EBITDA up 13.5% to $51.2 million. Gross margin held at 32.1% while operating income jumped to $39.8 million from $32.9 million, so growth is dropping through to profit rather than being bought with spending. Cash generation of $40.9 million in the quarter and a balance sheet with $98.5 million of cash against just $24.3 million of bank debt leaves ample room to fund the pending $275 million AccentCare personal care acquisition, which management reiterated is expected to close after regulatory approvals. The main thing that could move the stock from here is the November 4 conference call, where guidance and AccentCare integration timing will be the focus.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2240 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADUS was trading at $124.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $87.95 to $127.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.